Chen Gao

Dr. Chen Gao


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
CGChen Gao
Chen Gao
THTingting Huang
Tingting Huang
KWKerong Wu
Kerong Wu
WZWei Zhang
Wei Zhang
SWSheng Wang
Sheng Wang
CTChaoliang Tang
Chaoliang Tang
Background: Multimodal postoperative pain regimens are widely used following total knee arthroplasty (TKA). However, there are few studies on the rehabilitation of the co-application of local infiltration analgesia (LIA) and femoral nerve block (FNB) combined with dexmedetomidine (DEX) for patients undergoing TKA. This study aimed to investigate the effect of LIA plus FNB and co-application of perioperative DEX on TKA outcomes. Methods: 95 patients were randomized into two groups. Patients in group B (n = 48) received a single preoperative FNB and LIA. Patients in group A (n = 47) received FNB and LIA, as well as continuous intravenous injection of DEX starting from the induction of anesthesia to postoperative day 2. All patients were allowed patient-controlled analgesia postoperatively. Visual analog scale (VAS) scores, knee range of motion (ROM) degrees, narcotic consumption, length of hospital stay (LOS), complications, Hospital for Special Surgery (HSS) scores and Montreal Cognitive Assessment-Basic (MoCA-B) Scores were recorded. Results: In group A, the mean VAS scores at rest and during movement were lower, the amount of rescue analgesia was decreased, first time of ambulation was reduced, ROM was improved, MoCA-B Scores were increased, LOS was shorter, HSS scores were higher postoperatively compared with group B (all p < 0.05). Conclusion: Our study indicated multimodal analgesia involving a single FNB and LIA combined with DEX accelerates rehabilitation for patients undergoing TKA.

14 October 2024 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
KHKe Qiang He
Ke Qiang He
THTing Ting Huang
Ting Ting Huang
MTMeng Yuan Tan
Meng Yuan Tan
CGChen Gao
Chen Gao
SWSheng Wang
Sheng Wang
Introduction Ciprofol is a novel propofol analogue with a characteristic of hemodynamic stability. At present, there is a lack of research comparing the hemodynamic stability of ciprofol and propofol during painless colonoscopy. In this study, we aim to test the hypothesis that ciprofol is superior to propofol in terms of hemodynamic stability for sedation anesthesia in patients undergoing colonoscopy. Methods A total of 222 patients were randomized into two groups. Patients in group P (n = 112) and group C (n = 110) received propofol and ciprofol sedation, respectively. Noninvasive blood pressure were monitored starting from induction (T0) to the end of the procedure, at 2-min intervals (T1 to T10). Heart rate variability (HRV), pain injection, Modified Observer's Assessment of Alertness and Sedation (MOAA/S) score, body movement, doses of norepinephrine, modified Aldrete score, drug-related adverse reactions, and patient satisfaction and endoscopist satisfaction were recorded. Results In group C, fewer patients experienced a decrease in blood pressure with a higher HRV after induction sedation, the incidence of pain injection was reduced, the amount of norepinephrine dose was decreased, patient satisfaction was increased compared with group P (all P < 0.05). There were no significant differences in induction time, modified Aldrete score, alertness time, drug-related adverse reactions, and endoscopist satisfaction. Conclusions Our study indicated intravenous induction with ciprofol was superior, with regard to hemodynamic stability and reduced injection pain, than induction with propofol for anesthesia in patients undergoing painless colonoscopy. Trial Registration Chinese Clinical Trial Registry (ChiCTR2200061814).

1 September 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
HZHongrui Zhu
Hongrui Zhu
ZWZaibao Wang
Zaibao Wang
SDSheng Ding
Sheng Ding
CLChunliu Li
Chunliu Li
LXLi Xie
Li Xie
SWSheng Wang
Sheng Wang
Objective: This study aimed to compare the effects of fospropofol disodium and propofol on perioperative neurocognitive function in elderly patients undergoing total hip arthroplasty (THA), evaluating the non-inferiority of fospropofol disodium in preventing or reducing perioperative neurocognitive disorders (PND) and exploring optimal clinical anesthesia strategies. Methods: A total of 180 elderly patients (aged 65~80 years) scheduled for THA between November 2022 and November 2024 were randomly assigned to the fospropofol disodium group (Group F, n=90) or the propofol group (Group P, n=90). Cognitive function was assessed preoperatively (1 day before surgery) and postoperatively (1, 3, 7 days, and 1 month) using the Modified Mini-Mental State Examination (MMSE), 3-Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM), Digit Span Test (DST), Verbal Fluency Test (VFT), and Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). The incidence of postoperative cognitive dysfunction (POCD) and delirium (POD), hemodynamic parameters, and adverse events were compared between the two groups. Results: No significant differences were observed between the two groups in the incidence of POCD (p> 0.05) or POD (p> 0.05) at any postoperative time point. At the time point of 10 minutes after bone cement implantation (T4), the heart rate of patients in the Group F was higher than that of Group P (p < 0.0001). At the time of discharge from the PACU, the heart rate of patients in the Group F was lower than that of the Group P (p = 0.037). Group F exhibited higher mean arterial pressure (MAP) at the beginning of the operation (p=0.022) and a longer extubation time and waking time (p < 0.001) but had significantly lower incidences of injection pain (p=0.018) and postoperative nausea and vomiting (p=0.037). Binary logistic regression identified age as an independent risk factor for PND [OR=1.149, p=0.006], while preoperative MMSE score was a protective factor [OR=0.693, p = 0.002]. Conclusion: Fospropofol disodium may be a viable alternative in settings where injection pain and PONV are primary concerns, provided that hemodynamic stability is actively managed in elderly THA patients, with non-inferior efficacy in preventing PND compared to propofol and fewer adverse effects. Age and preoperative cognitive function are critical predictors of PND, warranting careful consideration in perioperative management.

1 September 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MXMin Xu
Min Xu
SWSheng Wang
Sheng Wang
YMYan Meng
Yan Meng
CGChen Gao
Chen Gao
LLLin Liu
Lin Liu
KHKeqiang He
Keqiang He
Purpose: This study aimed to compare the analgesic efficacy of liposomal bupivacaine with that of traditional ropivacaine in adductor canal blocks for patients undergoing knee arthroplasty. Patients and Methods: A total of 119 consenting participants, who were scheduled for elective knee arthroplasty (including total knee replacement and unicompartmental knee replacement) under general anesthesia, were randomly assigned to either receive an ultrasound-guided adductor canal block with ropivacaine or liposomal bupivacaine. The primary endpoint of this study was the pain scores at 2, 24, 48, and 72 hours post-surgery. Secondary outcomes included nausea, vomiting, and pruritis, the ability to engage in physiotherapy on the first day after surgery, postoperative exercise, patient satisfaction with anesthesia, postoperative recovery index, and patient-controlled analgesic presses (12– 48 hours) for both groups. Results: The Visual Analog Scale (VAS), assessed from 24 to 72 hours post-follow-up, demonstrated that patients receiving ropivacaine had higher median VAS scores compared to those in the liposomal bupivacaine group, both at rest and during exercise. The weighted AUC numerical rating scale pain scores whether at rest or move in the liposomal bupivacaine group was lower than the standard bupivacaine group with statistical significance. Whether it is 0– 24 hours (Rest 58.00 [53.75, 69.00] vs 48.00 [46.50, 58.00]; Move:57.00 [46.00, 59.00] vs 36.00 [35.00, 48.00]) or 0– 72 hours (Rest 214.00 [197.75, 237.00] vs 165.00 [143.50, 180.00]; Move:202.00 [190.00, 215.75]vs.156.00 [131.00, 178.00]) From 12 to 48 hours, the ropivacaine group had a significantly higher number of PCIA presses. The liposomal bupivacaine group also achieved greater pain-free bending angles and walking distances compared to the ropivacaine group. Conclusion: Liposomal bupivacaine used in adductor canal block provides extended pain relief in knee arthroplasty patients, aiding early rehabilitation.

26 March 2024 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
YYYang Yang
Yang Yang
CYChao Yang
Chao Yang
YSYujie Shi
Yujie Shi
CTChengyuan Tang
Chengyuan Tang
HWHanyu Wang
Hanyu Wang
YXYanhu Xie
Yanhu Xie
Several studies have shown that propofol administration during surgery effectively attenuates remifentanil-induced hyperalgesia (RIH). Ciprofol, a novel intravenous sedative agent analogous to propofol, has not yet been proven efficacious in alleviating RIH. The present study aimed to investigate the effect of ciprofol on RIH and the possible mechanisms involved. The RIH model was established by an infusion of remifentanil (1 μg·kg−1·min−1) 60 min in rats with incisional pain. Ciprofol (0.1, 0.25, and 0.4 mg·kg−1·min−1) was simultaneously infused to evaluate its effect on RIH. The antinociception of ciprofol was verified by measured paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL). γ-aminobutyric acid type A receptor α2 subunit (α2GABAAR), N-methyl-d-aspartate receptor NR2B subunit (NR2B), calcium/calmodulin-dependent protein kinase II α (CaMKIIα), and phosphorylated CaMKIIα (P-CaMKIIα) in the spinal cord and hippocampus of rats were assessed by western blotting and immunohistochemistry. The results showed that ciprofol dose-dependently increased PWMT and PWTL values in RIH rats. Moreover, ciprofol upregulated α2GABAAR and downregulated NR2B and P-CaMKIIα in the rat spinal cord and hippocampus. Ciprofol alleviates RIH effectively, and the anti-hyperalgesic mechanisms may involve increasing α2GABAAR levels and decreasing NR2B and P-CaMKIIα levels in the spinal cord and hippocampus.

1 November 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
YMYan Meng
Yan Meng
YSYouping Song
Youping Song
CGChen Gao
Chen Gao
SWSheng Wang
Sheng Wang
KHKeqiang He
Keqiang He
MXMin Xu
Min Xu
Background: Endoscopic Retrograde Cholangiopancreatography (ERCP) requires precise anesthesia control. Remimazolam is ideal for induction due to its rapid onset and minimal cardiorespiratory impact, but its optimal dose across ages is unclear. This study determined the median effective dose (ED50) of remimazolam for ERCP induction and assessed the influence of age. Methods: In this prospective study, 110 patients aged 50– 89 years (ASA I–III, BMI 18– 30 kg/m2) scheduled for ERCP were stratified into four age groups: R1 (50– 59), R2 (60– 69), R3 (70– 79), and R4 (80– 89). The Dixon up-and-down method was used, with the initial dose for R1 set at 0.1 mg/kg remimazolam and sequentially reduced by 0.01 mg/kg for the first patient in each older group. Patients received 0.1 μg/kg sufentanil prior to the intravenous administration of a predetermined dose of remimazolam. Anesthesia success was defined as a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of 0 at 3 minutes after intravenous remimazolam administration, which served as the endpoint for determining the effective induction dose. Results: To determine the effective dose for inducing anesthesia, the ED50 of remimazolam were calculated for groups R1 to R4 as follows: 0.122, 0.108, 0.093, and 0.078 mg/kg, respectively. Similarly, the dosage required to achieve ED95 for the same groups was determined to be 0.132, 0.122, 0.113, and 0.090 mg/kg.Bivariate and multivariable linear regression analyses confirmed a significant inverse correlation between age and remimazolam dose requirement (r = − 0.829, p < 0.001), with age remaining an independent predictor after adjusting for confounders. Conclusion: This study confirms a significant and independent inverse correlation between age and the required induction dose of remimazolam for ERCP. The ED50 decreases progressively with advancing age. We recommend a tailored reduction in the remimazolam induction dose for geriatric patients to enhance safety.